Abstract:Background: Neuroblastoma (NB) is the most common extra-cranial solid cancer in children. Although multimodal therapies with differentiating agents and immunotherapy with anti-GD2 antibody and GM-CSF have shown promising results, it remains deadly in approximately 50% of patients with high-risk disease. Chimeric antigen receptor T-cell therapies (CAR-T) have been found to be effective in treating refractory and relapsed leukemia and lymphoma, and two of them have been recently approved by the FDA. However, current CARs frequently lose efficacy due to T cell exhaustion and CARs against solid tumor antigens often lack enough specificity due to a low incidence of somatic mutations resulting in a paucity of tumor neoantigens. There have not been effective CAR-T therapies against other solid cancers to date although many clinical trials are underway. We previously identified 2 cell surface cancer-associated antigens, GPC2 (Glypican-2) and CD276 (B7-H3), both highly expressed in NB tumor cells but expressed at low or undetectable levels in normal organs. Here we attempt to develop a high throughput way of identifying optimal CART cell binders that show activation and expansion in the presence of GPC2 and CD276 but lack of exhaustion. Methods: Binders targeting GPC2 or CD276 were cloned into CAR lentiviral constructs and then were separately transduced into T cells to develop CAR-T cells. Then we analyzed cytotoxicity of these CART cells individually. To identify the most effective GPC2 or CD276-specific targeting CAR-T cells, we utilized a combined proteomics and transcriptomics method for every single CAR-T cell to quantify RNA and protein at the same. All CAR-T cells were pooled and co-cultured with CD276/GPC2-expressing NB cancer cells (target cells) for 24 hr. Co-cultured CAR-T cells were examined for their activation, exhaustion, cytotoxicity state and distinguished different cell types by staining with CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) antibodies, and then molecularly barcoded using 10X Genomics platform for single cell RNA-sequencing (scRNA-seq). Results: We attempted to test the efficacy of CAR-T cells using 14 established and novel binders against GPC2 or CD276. According to cytotoxicity assay of these 14 CART cells, we found CT3 was the most effective GPC2 targeting CART cells but majority of CD276 CART cells showed high cytolytic activity in vitro. Conclusions and Future Directions: Using the CITE-seq and RNAseq analyses, we can identify which of the CARs are enriched and have an activated T cell signature, but lack exhaustion markers. Top candidate binders for each antigen are currently being developed into “AND” or “OR” CARs that are being tested in in-vitro and in-vivo models of NB. Thus, we have developed a high throughput method to identify high affinity functional binders against tumor cell surface antigens and provide a novel immunogenomics methods of CARs optimization for development of highly effective immunotherapies against NB and other cancers. Citation Format: Meijie Tian, Adam Tai-Chi Cheuk, Yong Song, Sivasish Sindiri, Nan Li, Christopher M. Dower, Mitchell Ho, Bradley St Croix, Javed Khan. Immunogenomic approaches to optimize immunotherapeutic targeting of neuroblastoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5871.

Use of anti-GD2 (Dinutuximab) as a target for CAR-T cells immunotherapy in neuroblastoma

Choosing T-cell sources determines CAR-T cell activity in neuroblastoma

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma

Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma

CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

Abstract 5871: Immunogenomic Approaches to Optimize Immunotherapeutic Targeting of Neuroblastoma

GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma

Eradication of Medulloblastoma by NKG2D-specific CAR T-cells.

Developing CAR T-Cell Therapies for Pediatric Solid Tumors

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction

Abstract A13: Immunogenomic Approaches to Optimize Immunotherapeutic Targeting of Neuroblastoma

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma

Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

Cytokine-induced Killer Cells/natural Killer Cells Combined with Anti-Gd2 Monoclonal Antibody Increase Cell Death Rate in Neuroblastoma SK-N-SH Cells